Plain-English translation of NCT07677774 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new type of imaging scan called GPC3-targeted PET/CT, which is designed to help doctors find and monitor liver cancer tumors. The scan uses a special marker that attaches to cancer cells, making them easier to see. Researchers want to know if this new scan is better at detecting liver cancer than standard imaging tests.
Current imaging tests for liver cancer don't always catch all tumors, especially small ones or cancer that has spread. This trial exists to see if the new imaging approach can find cancers more reliably and help doctors make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive an injection of a special marker and then undergo a PET/CT imaging scan. The scan typically takes about 30–60 minutes and is painless. Your scan results will be compared with other imaging tests (like MRI) and pathology results if available to see how well the new scan detects liver cancer.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
China
Sponsor
The First Affiliated Hospital of Xiamen University
Enrollment target
~40 participants
Started
May 2026
Primary completion
May 2028
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Liang Zhao
The First Affiliated Hospital of Xiamen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.